Home Products Most Popular Contact
No items in your cart.
The page below is a sample from the LabCE course Advances in Noninvasive Prenatal Testing For Down Syndrome and other Trisomies. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Advances in Noninvasive Prenatal Testing For Down Syndrome and other Trisomies (online CE course) »
How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 111 CE courses, most popular
$95 Add to cart
Pick Your Courses
Up to 8 CE hours
$50 Add to cart
Individual course$20 Add to cart

Noninvasive Prenatal Testing (NIPT): Cell-free Fetal DNA (cffDNA), continued

Currently several highly specific and sensitive NIPT method are available as an alternative for prenatal screening tests. NIPT methods measure the level of circulating cell-free fetal DNA (cffDNA) present in maternal plasma to identify fetal aneuploidies, including Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13) as well as sex chromosome aneuploidies. cffDNA is genetic material that is released primarily by the placenta and circulates in the mother's blood during the pregnancy. cffDNA typically can be detected in maternal plasma as early as the fifth postmenstrual week and almost always is detected by the ninth postmenstrual week. Normally the percentage of fetal DNA increases with increasing gestational age.
Since fetal DNA represents a small percent of the total DNA in the maternal circulation, a major challenge with identifying cffDNA is separating fetal DNA from maternal DNA. At present, there are two major techniques for isolating fetal DNA from maternal DNA: Massively parallel signature sequencing (MPSS) and targeted DNA analysis.